ALVESCO
ICS MDI
Ciclesonide · Covis Pharma
Active Medication & Mechanism
- Ciclesonide ICS80 mcg or 160 mcg per actuation
Pro-drug that is enzymatically hydrolyzed in the lungs to its active metabolite desisobutyryl-ciclesonide (des-CIC), which has high glucocorticoid receptor affinity and anti-inflammatory activity.
FDA-Approved Dosing by Indication
// approval varies by strength + age Asthma
3/4 approved regimens| Strength | Population | Dose & Frequency | Total Daily | Status |
|---|---|---|---|---|
| 80 mcg | Patients ≥12 years (previously on bronchodilators alone) | 1 inhalation twice daily or 2 inhalations once daily Starting dose for patients previously using bronchodilators alone. | 160 mcg | FDA Approved |
| 80 mcg | Patients ≥12 years (previously on inhaled corticosteroids) | 1 inhalation twice daily or 2 inhalations once daily Starting dose for patients previously maintained on other inhaled corticosteroids. | 160 mcg | FDA Approved |
| 160 mcg | Patients ≥12 years (previously on oral corticosteroids) | 2 inhalations twice daily Higher dose for patients previously on oral corticosteroids. Maximum recommended dose is 320 mcg twice daily (640 mcg/day). | 640 mcg | FDA Approved |
| Any strength | Acute bronchospasm | — | — | Not Approved Not a bronchodilator and should not be used for relief of acute bronchospasm. |
COPD
0/1 approved regimens| Strength | Population | Dose & Frequency | Total Daily | Status |
|---|---|---|---|---|
| Any strength | Adults | — | — | Not Approved Alvesco is not indicated for COPD. |
Acute Use
0/1 approved regimens| Strength | Population | Dose & Frequency | Total Daily | Status |
|---|---|---|---|---|
| Any strength | Acute bronchospasm / rescue | — | — | Not Approved Not a rescue inhaler. Not indicated for acute episodes. Use a SABA. |